Mariner
LUCD icon

Mariner’s Lucid Diagnostics LUCD Stock Holding History

Mariner’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.3K Buy
21,153
+7,293
+53% +$9.28K ﹤0.01% 3482
2025
Q4 		$15.1K Buy
+13,860
New +$15.5K ﹤0.01% 3501
2025
Q2 		– Sell
-10,163
Closed -$15.1K – 3602
2025
Q1 		$15.1K Buy
+10,163
New +$12.2K ﹤0.01% 3395

Other funds holding LUCD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Mariner's LUCD Position: Q1 2026 in Review

Mariner increased its Lucid Diagnostics (LUCD) stake by 53% in Q1 2026, buying an estimated $9.28K and bringing the position to 21,153 shares worth $24.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3482.

Mariner first reported a position in LUCD in Q1 2025 and has held it in 3 quarters since. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • Mariner held 21,153 shares of Lucid Diagnostics worth $24.3K as of Q1 2026.
  • Mariner bought 7,293 Lucid Diagnostics shares in Q1 2026, an estimated $9.28K.
  • Lucid Diagnostics made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #3482 holding.
  • Mariner first reported a position in Lucid Diagnostics in Q1 2025 and has held it in 3 quarters since.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.